8-KItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Charles River reaffirms 2026 outlook and sets 2030 growth targets
Filed with the SEC on · Summarized by InvestorsBot
At its September 24, 2026 Investor Day, Charles River Laboratories reaffirmed its 2026 guidance, expecting revenue and non-GAAP EPS at the upper ends of ranges of 0%–1% organic revenue growth and $11.15–$11.45, respectively. Through 2030, the company targets 5%–7% annual organic revenue growth, approximately 24% non-GAAP operating margin, and low-double-digit annual non-GAAP EPS growth; it also expects its Create the Future program to generate more than $300 million in cumulative savings from 2027 through 2030.